Form 4: Invivyd Director Acquires Stock Options

Invivyd, Inc. director Kevin F. McLaughlin acquired 50,000 stock options with an exercise price of $1.04, vesting in full by May 19, 2027.

Summary

• Kevin F. McLaughlin, a Director at Invivyd, Inc., was granted 50,000 stock options on May 19, 2026.
• The exercise price for these options is $1.04 per share.
• These options will vest in full on May 19, 2027, or earlier if it's the date of the Issuer's 2027 Annual Meeting of Stockholders, provided McLaughlin remains in continuous service.
• The underlying securities are 50,000 shares of Common Stock.
• The filing indicates that McLaughlin is not subject to Section 16 reporting requirements beyond this transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports a standard stock option grant to a director, which is a common compensation practice and does not inherently signal positive or negative company performance.

Positives

• Director Kevin F. McLaughlin has been granted a significant number of stock options (50,000), indicating potential alignment of management interests with shareholder value.
• The exercise price of $1.04 suggests a potentially favorable entry point for the director, assuming future stock price appreciation.
• The vesting schedule ties the full vesting to a specific date or event, encouraging continued service and commitment.

Negatives

• The filing is a Form 4, which reports changes in beneficial ownership, and does not contain financial performance data or operational updates that could be considered negative.

Risks

• The value of the stock options is contingent on the future performance of Invivyd, Inc.'s stock price.
• There is a risk that the reporting person's continuous service requirement may not be met, potentially impacting vesting.
• The filing does not provide details on the rationale behind the option grant, leaving the specific strategic intent unclear.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and the stock price appreciation, with full vesting expected by May 19, 2027.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice across the biotechnology and pharmaceutical industries to incentivize leadership and align their financial interests with long-term company success and shareholder returns.

Stakeholder Impact

• Shareholders: The stock option grant aligns director incentives with potential future stock price appreciation, which can benefit shareholders if the company performs well.
• Employees: The grant does not directly impact employees but reflects standard executive compensation practices.
• Management: The grant provides a financial incentive for continued service and performance.

Next Steps

• Kevin F. McLaughlin to maintain continuous service through the vesting date.
• Invivyd, Inc. to hold its 2027 Annual Meeting of Stockholders, which could trigger earlier vesting of options.

Key Dates

Keywords

Invivyd, Inc., IVVD, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act, Kevin F. McLaughlin